Iterum Therapeutics plc Earnings Recaps
Q3 2025
Nov 14, 2025
Iterum Therapeutics reported steady initial progress in the commercialization of Orlynda, with early prescriptions showing positive traction among prescribers despite ongoing payer coverage challenges.
Key takeaways
- Over 280 prescriptions for Orlynda generated within the early weeks post-launch, with over 100 unique prescribers.
- Around 40% of prescriptions have been filled through specialty pharmacy partners, indicating initial acceptance despite limited payer decisions.
- Collaboration with major distributors McKesson and AmerisourceBergen underway to enhance accessibility for prescribers outside typical purchasing models.
- Positive feedback from physicians highlights Orlynda's potential to treat uncomplicated urinary tract infections effectively, especially in cases of antibiotic resistance.